Lv3
330 积分 2026-01-12 加入
Reconsidering statins in MASLD: beyond cardiovascular protection to multisystem benefit
20天前
已完结
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
20天前
已完结
Association of Plasma Lipoprotein(a) With Major Adverse Cardiovascular Events in MASLD With or Without Advanced Liver Fibrosis
20天前
已完结
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
20天前
已完结
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
20天前
已完结
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
2个月前
已完结
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
2个月前
已完结
Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin
2个月前
已完结
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
2个月前
已完结
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
2个月前
已完结
皖公网安备34019202002308
